Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant regimen would use you for a patient over 70 years old with resectable gastric cancer?
Related Questions
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
How do you dose FOLFOX when given with concurrent chemoradiation in esophageal adenocarcinoma?
When do you consider performing a diagnostic laparoscopy before neoadjuvant chemotherapy in pancreatic adenocarcinoma patients?
Would you offer adjuvant chemotherapy in a patient with MSS colon cancer who only has residual mucin left, without viable cancer cells despite no pre-operative chemotherapy, in the colon and lymph nodes?
Which adjuvant chemotherapy would you offer to a MSI high pancreatic cancer patient after Whipple?
How would you approach patient with known Lynch Syndrome who developed a gall bladder cancer which on pathologic testing of the tumor by PCR and immunohistochemistry is pMMR and MSS?
Would you typically offer adjuvant FOLFOX or XELOX to a pT4b pN0 colon cancer?
How would you manage a patient with metastatic HCC on atezolizumab/bevacizumab who requires holding bevacizumab due to persistent proteinuria >2g?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
How long do you treat with immunotherapy patients with MSI-high T4B initially unresectable colon adenocarcinoma?